Qritive
Bruno Occhipinti serves as the Chief Executive Officer and Chief Commercial Officer at Qritive since June 2022, where the focus is on expanding AI-powered solutions for pathology. Previously, from May 2021 to May 2022, Occhipinti was the General Manager at AICS, leading a team of over 20 in an AI-for-Healthcare initiative, securing partnerships with large public hospitals, and co-developing AI-assisted solutions. Prior experience includes founding CrestaLab, where the emphasis was on building health ecosystems for equitable care, and significant roles at Philips and Samsung Electronics, contributing to strategic growth in health technology and renewable energy sectors, respectively. Occhipinti holds an MBA from The Wharton School and advanced degrees from the University of Pennsylvania and other esteemed institutions.
This person is not in any teams
Qritive
Qritive makes cancer diagnosis fast, cheap, and accurate. Qritive develops AI-powered solutions that enable histopathologic diagnosis of cancer at scale. Our clinical-decision support system for pathologists unlocks efficiency and quality gain in diagnosis, which results in better patient outcome. It includes AI Modules, an Image Management System platform (Pantheon), and a network of pathologists on-demand for services (annotations, 2nd opinion...) Our digital pathology platform has been used by several healthcare institutions in Singapore, India, Morocco, UAE, and USA, and the results have been presented at various events and journals: USCAP 2023 (deep learning on prostate biopsies), 2022 (Ki-67 on Sarcomas), and 2021 (colorectal malignancies), or Nature Scientific Report.